To evaluate if resistance was selected from preexisting tumor subclones or was acquired in vitro in response to trametinib, allele-specific ddPCR assays for the MEK1/2 mutations were conducted in both the original tumor biopsy specimen and the parental cells (Supplementary Fig. S3A). This evidence concerns the gene MAP2K1 and neoplasm.